Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

The potential for vigabatrin-induced intramyelinic edema in humans.

Cohen JA, Fisher RS, Brigell MG, Peyster RG, Sze G.

Epilepsia. 2000 Feb;41(2):148-57. Review.

2.

Non-vision adverse events with vigabatrin therapy.

Walker SD, Kälviäinen R.

Acta Neurol Scand Suppl. 2011;(192):72-82. doi: 10.1111/j.1600-0404.2011.01602.x. Review.

PMID:
22061182
3.

Vigabatrin: 2008 update.

Willmore LJ, Abelson MB, Ben-Menachem E, Pellock JM, Shields WD.

Epilepsia. 2009 Feb;50(2):163-73. Review.

PMID:
19230067
4.

Vigabatrin: effects on human brain GABA levels by nuclear magnetic resonance spectroscopy.

Mattson RH, Petroff O, Rothman D, Behar K.

Epilepsia. 1994;35 Suppl 5:S29-32. Review.

PMID:
8039467
5.

Vigabatrin.

Mumford JP, Cannon DJ.

Epilepsia. 1994;35 Suppl 5:S25-8. Review.

PMID:
8039466
6.

[Acute encephalopathy and myoclonic status induced by vigabatrin monotherapy] .

García Pastor A, García-Zarza E, Peraita Adrados R.

Neurologia. 2000 Oct;15(8):370-4. Review. Spanish.

PMID:
11143506
7.

Vigabatrin.

French JA.

Epilepsia. 1999;40 Suppl 5:S11-6. Review.

8.

Vigabatrin-associated retinal damage: potential biochemical mechanisms.

Heim MK, Gidal BE.

Acta Neurol Scand. 2012 Oct;126(4):219-28. doi: 10.1111/j.1600-0404.2012.01684.x. Epub 2012 May 26. Review.

PMID:
22632110
9.

Current role of vigabatrin in infantile spasms.

Parisi P, Bombardieri R, Curatolo P.

Eur J Paediatr Neurol. 2007 Nov;11(6):331-6. Epub 2007 Jul 10. Review.

PMID:
17625936
10.

Justification of vigabatrin administration in West syndrome patients? Warranting a re-consideration for improvement in their quality of life.

Jaseja H.

Clin Neurol Neurosurg. 2009 Feb;111(2):111-4. doi: 10.1016/j.clineuro.2008.08.004. Epub 2008 Oct 8. Review.

PMID:
18845383
11.

Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.

EFSA GMO Panel Working Group on Animal Feeding Trials.

Food Chem Toxicol. 2008 Mar;46 Suppl 1:S2-70. doi: 10.1016/j.fct.2008.02.008. Epub 2008 Feb 13. Review.

PMID:
18328408
12.

Vigabatrin for tuberous sclerosis complex.

Curatolo P, Verdecchia M, Bombardieri R.

Brain Dev. 2001 Nov;23(7):649-53. Review.

PMID:
11701271
13.

[Epilepsy and Sabril].

Depasse F.

Bull Soc Belge Ophtalmol. 2007;(304):33-40. Review. French.

PMID:
17718226
14.

[Influence of vigabatrin on visual fields and electrophysiological tests in patients with epilepsy].

Mrugacz M, Bakunowicz-Łazarczyk A.

Klin Oczna. 2003;105(5):326-8. Review. Polish.

PMID:
14746191
15.

Steroids or vigabatrin in the treatment of infantile spasms?

Riikonen RS.

Pediatr Neurol. 2000 Nov;23(5):403-8. Review.

PMID:
11118795
16.

Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval.

Tolman JA, Faulkner MA.

Expert Opin Pharmacother. 2009 Dec;10(18):3077-89. doi: 10.1517/14656560903451690. Review.

PMID:
19954276
17.

ACS chemical neuroscience molecule spotlight on Sabril.

Hopkins CR.

ACS Chem Neurosci. 2010 Jul 21;1(7):475. doi: 10.1021/cn100025k. Review.

18.

Mechanism of action of vigabatrin: correcting misperceptions.

Ben-Menachem E.

Acta Neurol Scand Suppl. 2011;(192):5-15. doi: 10.1111/j.1600-0404.2011.01596.x. Review.

PMID:
22061176
19.

Postmarketing studies.

Sussman NM.

Adv Neurol. 1998;76:263-6. Review. No abstract available.

PMID:
9408485

Supplemental Content

Support Center